ArticleDigestive diseases and sciences2026
Incidence of Cardiovascular Events and Extrahepatic Malignancies in Steatotic Liver Disease Subgroups.
Article in Digestive diseases and sciences, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Understanding the economic and healthcare burden of metabolic dysfunction-associated steatohepatitis: a real-world claims data analysis from Germany.Journal of comparative effectiveness research · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
purposePeople with metabolic dysfunction-associated steatotic liver disease (MASLD) or alcohol-related liver disease (ALD) are at increased risk of cardiovascular (CV) events and extrahepatic cancers. However, data on MASLD with increased alcohol intake (MetALD) are limited. We investigated the incidence of CV events and extrahepatic cancers across SLD subgroups.
methodsPatients with histologically confirmed SLD were included. Incident CV events (heart failure, ischemic heart disease (IHD), cerebrovascular disease, peripheral vascular disease) and extrahepatic cancers were recorded. Five-year cumulative incidence and sHR were estimated using competing risk regression with death and transplantation as competing events.
results739 patients were included: 525 (71%) MASLD, 88 (12%) MetALD and 126 (17%) ALD. Mean age was 51 ± 13 years and 63% were male. Advanced fibrosis (F ≥ 3) was present in 39%. Over a median follow-up of 6.3 (IQR 3.8-8.3) years, 75 (10.1%) patients died, and 60 incident CV events occurred, most commonly IHD (46.6%). Estimated five-year cumulative incidence of CV events was 5.3% in MASLD, 7.4% in MetALD and 3.2% in ALD. Extrahepatic cancers occurred in 55 patients, most frequently skin and prostate. Estimated five-year cumulative incidence of extrahepatic cancers was 3.4% in MASLD, 4.9% in MetALD and 4.3% in ALD. The SLD subgroup was not independently associated with CV events, but MetALD (sHR 2.43, p = 0.021) and ALD (sHR 1.96, p = 0.040) were independently associated with extrahepatic cancer risk.
conclusionsIn this cohort of biopsy-proven SLD, the risk of extrahepatic cancer was higher in patients with MetALD. These findings may reflect synergistic effects of metabolic risk and alcohol exposure.
Indexed as
Identifiers
42230455What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.